Etizolam

From Self-sufficiency
Jump to: navigation, search
Etizolam
File:Etizolam.svg
File:Etizolam3d.png
Systematic (IUPAC) name
7-(2-chlorophenyl)- 4-ethyl- 13-methyl- 3-thia- 1,8,11,12- tetraazatricyclo [8.3.0.02,6}] trideca- 2(6),4,7,10,12- pentaene
Clinical data
Pregnancy
category
  •  ?
Routes of
administration
Oral
Legal status
Legal status
  • US: Unscheduled
Pharmacokinetic data
Bioavailability 93%
Metabolism Hepatic
Biological half-life about 6 hours
Excretion Renal
Identifiers
CAS Number 40054-69-1
ATC code N05BA19 (WHO)
PubChem CID 3307
DrugBank ?
Chemical data
Formula C17H15ClN4S
Molar mass 342.8[[Script error: No such module "String".]]
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Etizolam (marketed under the brand name Etilaam, Sedekopan, Pasaden or Depas) is a thienodiazepine drug which is a benzodiazepine analog. The etizolam molecule differs from most other benzodiazepines in that the benzene ring has been replaced by a thiophene ring.[1] It possesses amnesic, anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant properties.[2]

Indications

Dosage

  • For anxiety: 0,25-0,50 mg two or three times per day (maximum 2 mg per day)
  • For insomnia: 1 or 2 mg before bedtime

Side effects

Very Rare

Tolerance, dependence and withdrawal

Abrupt or over rapid withdrawal from etizolam as with other benzodiazepines may result in the appearance of the benzodiazepine withdrawal syndrome, including rebound insomnia.[7] A neuroleptic malignant syndrome, a rare event in benzodiazepine withdrawal has been documented in a case of abrupt withdrawal from etizolam.[8]

Contraindications and special caution

Benzodiazepines require special precaution if used in the elderly, during pregnancy, in children, alcohol or drug-dependent individuals and individuals with comorbid psychiatric disorders.[9]

Pharmacology

Etizolam a thienodiazepine benzodiazepine derivative, is absorbed fairly rapidly with peak plasma levels achieved between 30 minutes and 2 hours and has a mean elimination half life of about 3 and a half hours. However, its pharmacologically active metabolite alpha-hydroxyetizolam which has the same potency as etizolam is eliminated more slowly with a mean half life of just over 8 hours. So it can be classified as a short-medium action benzodiazepine.[10] Etizolam possesses potent hypnotic properties.[11] Etizolam acts as a full agonist at the benzodiazepine receptor to produce its range of therapeutic as well as adverse effects.[12] Similar to other benzodiazepines etizolam binds unselectively to benzodiazepine receptor subtypes.[13]

In addition etizolam unlike most other benzodiazepines has prolactogenic effects leading to an increase in prolactin blood levels.[14]

According to the Italian P.I. sheet etizolam belongs to a new class of diazepines, thienotriazolodiazepines. This new class is easily oxidized, rapidly metabolized, and has a lower risk of accumulation, even after prolonged treatment. Etizolam has an anxiolytic action about 6 times greater than that of diazepam. Etizolam produces, especially at higher dosages, a reduction in time taken to fall asleep, an increase in total sleep time and a reduction in the number of awakenings. During tests there were not substantial changes in deep sleep. There is a reduction of REM sleep. In EEG tests of healthy volunteers Etizolam showed some characteristics of tricyclic antidepressants.[4]

Interactions

Itraconazole and fluvoxamine slow down the rate of elimination of etizolam leading to accumulation of etizolam and thus increased pharmacological effects.[15][16] Carbamazepine speeds up the metabolism of etizolam resulting in reduced pharmacological effects of etizolam.[17]

Overdose

Etizolam has been used in cases of suicidal benzodiazepine overdose. An overdose of etizolam can prove fatal.[18]

Abuse

Etizolam is a drug of potential abuse. Etizolam has been shown to be able to substitute for the behavioural effects of barbiturates in primate studies.[19]

See also

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

External links

ja:エチゾラム
  1. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  2. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  3. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  4. 4.0 4.1 "Depas". Retrieved February 3, 2009. 
  5. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  6. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  7. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  8. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  9. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  10. Fracasso C, Confalonieri S, Garattini S, Caccia S (1991). "Single and multiple dose pharmacokinetics of etizolam in healthy subjects". Eur. J. Clin. Pharmacol. 40 (2): 181–5. PMID 2065698. 
  11. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  12. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  13. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  14. Kaneda Y (2000). "Short Communication: Prolactogenic effects of etizolam". Neuro Endocrinol. Lett. 21 (6): 475–476. PMID 11335869. 
  15. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  16. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  17. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  18. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  19. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.